Physician

Dennis F Moore, MD

According to 2025 Medicare claims, Dennis Moore, MD (NPI: 1043272305) practices hematology/oncology in the Wichita, KS market, with the plurality of this provider's patient population coming from Sedgwick, KS. This provider's primary affiliated billing organization is CANCER CENTER OF KANSAS, P.A. (NPI: 1841251394; TIN: 481181579) and primary practice location at 67214-3728. Moore is affiliated with the Aledade 38 KS CHC MSSP Enhanced (ACO ID: A4546) and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Moore's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,713 traditional Medicare patients, billed 533,866 HCPCS/CPT codes, and received $9,673,691 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,879 prescription claims across 312 beneficiaries totaling $5,070,658 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 154 claims. Open Payments data shows 123 records totaling $2,637. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $5,028,870 to $9,673,691. Similarly, Part D prescription costs have risen steadily, from $2,735,189 to $5,070,658. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $27,756 to $883.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,467	337,259	$5,028,870
2016	1,433	450,761	$5,282,414
2017	1,452	390,508	$4,638,935
2018	1,504	454,181	$6,417,068
2019	1,414	483,906	$6,821,369
2020	1,326	443,847	$6,787,676
2021	1,093	364,813	$5,504,292
2022	1,117	349,135	$5,673,104
2023	1,534	465,810	$8,881,208
2024	1,713	533,866	$9,673,691

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	341	2,307	$2,735,189
2016	334	2,305	$2,839,677
2017	369	2,542	$3,474,548
2018	365	2,512	$4,315,920
2019	359	2,489	$4,650,568
2020	357	2,460	$5,273,489
2021	334	2,126	$4,619,949
2022	315	1,912	$4,610,422
2023	290	1,741	$3,439,306
2024	312	1,879	$5,070,658

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	106	463	$117,015
2016	124	376	$77,852
2017	70	268	$60,766
2018	27	280	$33,250
2019	30	160	$12,844
2020	25	98	$7,534
2021	11	143	$9,217
2022	22	93	$4,687
2023	N/R	101	$22,463
2024	N/R	154	$3,674

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	421	1,156	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	649	1,493	$87
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	499	850	$12
96372	Injection of drug or substance under skin or into muscle	423	1,030	$10
36415	Insertion of needle into vein for collection of blood sample	422	2,156	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	52	1,316	$1,004,617
Calquence	Acalabrutinib Maleate	58	1,740	$865,108
Venclexta	Venetoclax	51	1,474	$545,589
Promacta	Eltrombopag Olamine	16	480	$487,027
Imbruvica	Ibrutinib	19	532	$303,461

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	46	$1,378
J8521	Capecitabine, oral, 500 mg	N	N/R	25	$937
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	51	$640
K0001	Standard wheelchair	Y	N/R	12	$381
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	20	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	123	$2,637	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dennis F. Moore, MD?

Tedicare shows public-source Medicare data for Dennis F. Moore, MD (NPI 1043272305), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dennis F. Moore, MD have ACO affiliation data?

Dennis F. Moore, MD is shown with ACO affiliation data for Aledade 38 KS CHC MSSP Enhanced (MSSP, ACO ID A4546) and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Dennis F. Moore, MD?

Dennis F. Moore, MD is linked to CANCER CENTER OF KANSAS, P.A. (billing NPI 1841251394) in the available physician profile data.

Does Dennis F. Moore, MD have Open Payments data?

Dennis F. Moore, MD has 123 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.